# A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes

> **NCT06559722** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Tonghua Dongbao Pharmaceutical Co.,Ltd** · enrollment: 510 (estimated)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Insulin Degludec/liraglutide Injection
- **DRUG:** XULTOPHY®

## Key facts

- **NCT ID:** NCT06559722
- **Lead sponsor:** Tonghua Dongbao Pharmaceutical Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-08
- **Primary completion:** 2025-10
- **Final completion:** 2026-02
- **Target enrollment:** 510 (ESTIMATED)
- **Last updated:** 2024-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06559722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06559722, "A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06559722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*